Doctors' Decision-Making Tool Could Cut Unnecessary Antibiotic Use

Doctors' Decision-Making Tool Could Cut Unnecessary Antibiotic Use

A new decision-making tool for doctors may help reduce unnecessary use of antibiotics in children with respiratory tract infections and cough, researchers report.

Using information from more than 8,000 children, the investigators identified seven key predictors that could be used to help determine whether a child with a respiratory tract infection and cough is likely to require antibiotics.

Those predictors are: short illness (less than three days); fever of 100 F or higher; younger than 2 years old; respiratory distress; wheeze; asthma; and moderate/severe vomiting in the previous 24 hours.

Children with none, or just one, of these predictors are at very low risk of future complications, the researchers said.

If antibiotic use in low-risk children was halved -- and even if it increased 90 percent in high-risk children during the same time -- this decision-making tool could reduce antibiotic use among children with respiratory infection and cough by 10 percent, the findings suggested.

Further research is needed to confirm the validity of the tool, the study authors added.

The findings were published Sept. 1 in The Lancet Respiratory Medicine.

published in: 2016-09-04 10:40:56

FDA Cracks Down on Antibacterial Soaps

FDA Cracks Down on Antibacterial Soaps

FRIDAY Sept. 2, 2016, 2016 -- The U.S. Food and Drug Administration is banning most antibacterial soaps and body washes currently on store shelves, arguing that the products create potential health risks but don't perform any better than plain old soap and water.

The ban covers soaps and body washes containing triclosan and triclocarban, the two most common antibacterial ingredients, the FDA says. Another 17 active ingredients also are included in the ban.

"Most consumer wash products labeled 'antibacterial' or 'antimicrobial' contain at least one of the antibacterial ingredients addressed in this final rule," said Dr. Theresa Michele, director of the Division of Nonprescription Drug Products at the FDA's Center for Drug Evaluation and Research.

There are more than 2,100 antibacterial soaps sold today, representing about 40 percent of the overall soap market, Michele said during a media briefing Friday.

The agency said it took this action over concerns that antibacterial soaps might be contributing to bacterial resistance.

In the United States, at least 2 million people a year become infected with antibiotic-resistant bacteria, and at least 23,000 die from these infections, according to the...

published in: 2016-09-04 10:32:51

Takeda Pharmaceutical : Deerfield's Takeda gets $19.8 million to develop Zika vaccine

Takeda Pharmaceutical : Deerfield's Takeda gets $19.8 million to develop Zika vaccine

Takeda Vaccines, a subsidiary of Japanese drugmaker Takeda Pharmaceutical Co., will get the funding over the next 18 months, according to the U.S. Department of Health and Human Services. Takeda's commercial U.S. headquarters is in Deerfield.

...

published in: 2016-09-04 09:14:39

Hydrocolloids Market to Reach $9.39 Billion with 6.58% CAGR Forecast to 2022

Hydrocolloids Market to Reach $9.39 Billion with 6.58% CAGR Forecast to 2022

According to RESEARCH, the Hydro Colloids Market accounted for $6.01 Billion in 2015 and is expected to grow at a CAGR of 6.58% to reach $9.39 Billion by 2022. Growing number of expendable income, improving functionalities and developing new innovations in colloids,Increasing health awareness among people and developing economic environments are the factors driving the market growth. However, volatility of raw material prices and lack of resources are the factors restraining the market growth. Moreover, promising markets will have a huge potential in hydrocolloids and growing consumptions of expediency foods are the major opportunities in this market over the forecast period.

Synthetic Hydrocolloids
o Methyl cellulose (MC)
o Hydroxy Ethyl Methyl Cellulose (HMC)
o Hydroxy Propyl Methyl Cellulose (HPMC)
• Microbial Hydrocolloids
o Xanthun GUM
• Seaweed Hydrocolloids
o Alginates
o Carrageenan
o Agar
• Plant Hydrocolloids
o Carboxymethyl Cellulose (CMC)
o Pectin
o GUM Arabic
o Locust Bean GUM
o Guar GUM
• Animal Hydrocolloids
o Gelatin
Application Covered:
• Bakery
• Beverages
• Meat & Poultry Products
• Dairy and Frozen Products
• Oil and gas
• Pharmaceutical
• Textiles
• Confectionery
• Sauces & Dressings
• Paper and paperboard industries
• Other Applications
Forms Covered:
• Powder
• Gel
• Others

...

published in: 2016-09-03 00:46:26

Water Soluble Polymers Market (Material, Production, Geography) 2016 Analysis and Forecast to 2022

Water Soluble Polymers Market (Material, Production, Geography) 2016 Analysis and Forecast to 2022

According to researcher, the Global Water Soluble Polymers Market is estimated to be $34.7 billion in 2015 and is expected to reach $46.5 billion by 2022, growing at a CAGR of 4.3%. Increasing per capita consumption in economies such as of China and Southeast Asia is anticipated to drive the market in segments including food, personal care and pharmaceuticals. Some of the major challenges of the market include fluctuating raw material prices, and regulatory issues. Increasing environmental concern and rising efforts to modernize municipal water treatment facilities is expected to supplement the industry growth.

Some of the key players in the global water soluble polymers market include AkzoNobel, E. I. DU Pont De Nemours, Kuraray Group, LG Chem Ltd., BASF SE, The Dow Chemical Company, Kemira OYJ, Ashland Inc, Arkema S.A., SNF SAS, Gantrade, Nitta Gelatin Inc, Sumitomo Seika Chemicals Company, CP Kelco, and Shandong polymers Bio-chemicals Co. Ltd.
Raw Materials Covered:
• Natural
• Synthetic
• Semisynthetic
Types of Water Soluble Polymers Covered:
• Polyacrylamide and Copolymers
• Guar Gum and Derivatives
• Casein and Caseinates
• Polyvinyl Alcohol
• Polyacrylic Acid
• Gelatin
• Cellulose ether
• Xanthan gum
• Others
Applications Covered:
• Personal care & detergents
• Pharmaceuticals
• Oil & gas
• Agriculture
• Textiles
• Food
• Water Treatment
• Paper Making
• Petroleum
• Others

...

published in: 2016-09-03 00:44:18

Al Dawaa launches e-store on Souq.com in Saudi Arabia

Al Dawaa launches e-store on Souq.com in Saudi Arabia
Souq.com, a leading online retail and marketplace platform in the Middle East, has announced the launch of an exclusive e-store of the award winning Al Dawaa Pharmacies in Saudi Arabia.


The renowned pharmacy is a leader in Saudi Arabia for distributing pharmaceutical products of reputed brands at affordable prices in one integrated package. Boasting 600 chains across the kingdom and awarded as one of the top 100 Saudi brands in 2015, Al Dawaa Pharmacies is committed to the development of the kingdom's healthcare sector and providing optimal products in the pharmaceutical division to the consumers.

Al Dawaa Pharmacies has partnered with Souq.com to expand its reach online and become the first and the only online shopping destination for consumers to purchase products related to their personal and cosmetic needs in the kingdom, said the statement.
 

...

published in: 2016-08-28 16:26:42

Study examines reasons for high cost of prescriptions drugs in US

Study examines reasons for high cost of prescriptions drugs in US

High prescription drug prices are attributable to several causes, including the approach the U.S. has taken to granting government-protected monopolies to drug manufacturers, and the restriction of price negotiation at a level not observed in other industrialized nations, according to a study appearing in the August 23/30 issue of JAMA.

Drug prices are higher in the United States than in the rest of the industrialized world because, unlike that in nearly every other advanced nation, the U.S. health care system allows manufacturers to set their own price for a given product. In contrast, in countries with national health insurance systems, a delegated body negotiates drug prices or rejects coverage of products if the price demanded by the manufacturer is excessive in light of the benefit provided; manufacturers may then decide to offer the drug at a lower price.

The most important factor that allows manufacturers to set high drug prices is market exclusivity, protected by monopoly rights awarded upon Food and Drug Administration approval and by patents. The availability of generic drugs after this exclusivity period is the main means of reducing prices in the United States, but access to them may be delayed by numerous business and legal strategies.

Although prices are often justified by the high cost of drug development, there is no evidence of an association between research and development costs and prices; rather, prescription drugs are priced in the United States primarily on the basis of what the market will bear.

The researchers write that the most realistic short-term strategies to address high prices include enforcing more stringent requirements for the award and extension of exclusivity rights; enhancing competition by ensuring timely generic drug availability; providing greater opportunities for meaningful price negotiation by governmental payers; generating more evidence about comparative cost-effectiveness of therapeutic alternatives; and more effectively educating patients, prescribers,...

published in: 2016-08-27 16:05:52

AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer's disease

AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer's disease

AstraZeneca and Eli Lilly and Company (Lilly) today announced they have received US Food and Drug Administration (FDA) Fast Track designation for the development programme in Alzheimer's disease for AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in Phase III clinical trial. The FDA's Fast Track programme is designed to expedite the development and review of new therapies to treat serious conditions and tackle key unmet medical needs.

Alzheimer's disease is a fatal illness and is the most common form of dementia, accounting for 60 to 80 percent of cases. There are currently an estimated 46 million people living with dementia worldwide, and this number is expected to exceed than 74 million in 2030 and 131 million in 2050. Only 50 percent of people with dementia ever receive a formal diagnosis, and Alzheimer's disease continues to be one of the most significant health challenges facing the world. The total estimated worldwide cost of dementia in 2015 was $818 billion. By 2018, dementia will become a trillion dollar disease, rising to $2 trillion by 2030.

...

published in: 2016-08-23 09:53:42

Diabetes drug may also offer vascular protection

Diabetes drug may also offer vascular protection

Obesity and Type 2 diabetes are associated with vascular stiffening and the development of cardiovascular disease. Obese and diabetic premenopausal women are most at risk - even more than men of the same age who have similar health issues. A study by University of Missouri School of Medicine researchers found that a diabetes medication offered protection against arterial stiffness in overweight female mice, a finding that may have future implications for disease prevention in humans.

...

published in: 2016-08-22 08:25:11

FDA approves implantable device that changes the shape of the cornea to correct near vision

FDA approves implantable device that changes the shape of the cornea to correct near vision

June 29, 2016 -- The U.S. Food and Drug Administration today approved the Raindrop Near Vision Inlay, a device implanted in the cornea (the clear, front surface) of one eye to improve near vision in certain patients with presbyopia. It is the second FDA-approved implantable corneal device for correction of near vision in patients who have not had cataract surgery and the first implantable device that changes the shape of the cornea to achieve improved vision. 

...

published in: 2016-08-18 10:15:52